GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Advagene Biopharma Co 6709.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

21.60

+3.85%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Advagene Biopharma Co

Its shares trade on Taipei Exchange under the ticker 6709.TWO. It has been listed since 29 November 2018.

Advagene Biopharma Co., Ltd. engages in the development of products such as nasal influenza vaccine, airway allergy immunotherapy and COVID-19 immunotherapy. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-11-29. The products developed by the Company include nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy) and other vaccines. The detoxified LT adjuvant is genetically engineered to detoxify the heat-labile LT protein (or Escherichia coli heat-labile enterotoxin protein) produced by Escherichia coli.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
29 Nov 2018

Leadership

Pay as last reported

  • Mr. Yi-Shiuh HwangChairman of the Board, since 2016
  • Guoshu PengExecutive Vice President
  • Mr. Yu-Shen HsuGeneral Manager, Director, since 2014
  • Ms. Rongdun SuHead of Accounting
  • Mingyi ZhangChief Research & Development Officer
  • Mr. Bryon ChenDirector, since 2014
  • Meihui LiDirector
  • Qirui LiDirector
  • Qinyi XiaoDirector
  • Guiheng ChenIndependent Director
  • Yahui HuangIndependent Director
  • Weiling ZhuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Advagene Biopharma's nasal influenza vaccine LT-Flu targets respiratory health needs in Taiwan.
  • LT-Allergy allergy vaccines address growing allergy treatment demands in Asia.
  • Detoxified LT adjuvant technology enhances vaccine safety and efficacy globally.

Weaknesses

  • Limited product portfolio beyond nasal vaccines and allergy treatments in Taiwan.
  • Dependence on single adjuvant technology for multiple vaccine applications.
  • Nasal vaccine market penetration remains low in global health care sectors.

Opportunities

  • Expanding nasal vaccine market in Asia Pacific with rising respiratory illness rates.
  • Increasing demand for allergy treatments across Southeast Asia's growing population.
  • Global adoption of detoxified LT adjuvant in new vaccine development pipelines.

Threats

  • Regulatory hurdles for nasal vaccines in European health care systems.
  • Competition from established pharmaceutical companies in allergy treatments.
  • Potential supply chain disruptions affecting vaccine production in Taiwan.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.